Eight Roads Invests in Westlake Therapeutics

(VCBeat) Mar. 8, 2021 -- Eight Roads has recently announced the completion of a Series Pre-A+ round of investment in Westlake Therapeutics, further deepen its layout in the field of cell therapy.

RBC-based cellular drug development is a very innovative and challenging frontier field. Westlake Therapeutics is the first company focusing on RBC therapy in China. The company now has a leading engineered RBC therapeutic platform technology -- "REDx". Westlake Therapeutics has developed a number of innovative therapies for rare diseases, cancers, immunology and metabolism, taking advantage of the natural characteristics of RBC that are capable of loading large amounts of drugs, good biocompatibility, low immunogenicity, entire biodegradability, and a long-term circulation for nearly 120 days.

 Dr. Gao Xiaofei, the founder of Westlake Therapeutics, said: "We are glad to get Eight Roads' support with recognition of our vision and innovation methods. We believe that its strategic investment layout and international vision rooted in life sciences can bring our RBC-based cellular drugs to clinical verification. With the support of Eight Roads, we are able to recruit talents  globally and accelerate preclinical research and discovery to further realize the potential of engineered RBC therapeutic technology in the field of medical treatment and realize our vision of delivering more innovative treatment solutions with clinical significance."

Since 1969 Eight Roads have been partnering with ambitious technology and healthcare founders from all across the world. Its global ventures platform is one of the largest in the world, with teams investing in Asia, Europe, Israel and the US. With over 25 years of venture capital experience in China and has invested in more than 110 companies in the healthcare sectors. In the last 10 years, It has invested nearly $6 billion in startups worldwide.